Form 4: Inmune Bio Chief Scientific Officer Acquires 140,000 Stock Options

Inmune Bio's Chief Scientific Officer, Mark William Lowdell, was granted 140,000 stock options on December 5, 2024, which will vest in two years.

Summary

• Mark William Lowdell, the Chief Scientific Officer of Inmune Bio, Inc., has reported a transaction involving the acquisition of stock options.
• On December 5, 2024, Lowdell was granted 140,000 stock options at an exercise price of $5.05 per share.
• These options are granted under the company's 2021 Stock Incentive Plan.
• The options will become fully vested and exercisable on December 5, 2026, which is two years after the grant date.
• The options expire on December 4, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There is no indication of any negative sentiment.

Positives

• The grant of stock options to the Chief Scientific Officer aligns his interests with the long-term success of the company.
• The vesting period of two years encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize key personnel and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in the biotech industry, similar to companies like Amgen, Regeneron, and Gilead Sciences.
• The vesting period of two years is also typical, aligning with industry norms for long-term incentive plans.

Stakeholder Impact

• The stock option grant may positively impact shareholder confidence by aligning management's interests with the company's long-term success.
• The grant incentivizes the Chief Scientific Officer to contribute to the company's growth and value creation.

Key Dates

Keywords

stock options, insider trading, executive compensation, equity, Inmune Bio, INMB, Mark William Lowdell